KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Assets Average (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Assets Average for 14 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 5.96% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 5.96% increase, with the full-year FY2025 number at $1.4 billion, up 6.61% from a year prior.
  • Assets Average was $1.4 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.7 billion in Q1 2023 to a low of $1.3 billion in Q4 2023.
  • A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: rose 28.14% in 2021, then decreased 26.12% in 2024.
  • Supernus Pharmaceuticals' Assets Average stood at $1.6 billion in 2021, then grew by 4.67% to $1.7 billion in 2022, then decreased by 24.53% to $1.3 billion in 2023, then grew by 5.77% to $1.4 billion in 2024, then grew by 5.96% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).